e-Drug3D

1925

GILTERITINIB

INN
GILTERITINIB

cas 1254053-43-4

CLASS

ANTINEOPLASTIC
TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH A FLT3 MUTATION
TYROSINE KINASES INHIBITOR
INHIBITOR OF FMS-LIKE TYROSINE KINASE 3 (FLT3) INCLUDING FLT3-D835Y AND FLT3-ITD-D835Y MUTATIONS

ROUTE (list)

ORAL

ATC code

L01EX13

PK parameters

Tmax 5 HOUR
Cmax 0.67 MICROMOLAR
VD 1092 LITER
Cl 14.85 LITER / HOUR
PPB 94 PERCENT
t1/2 113 HOUR

Solubility

SPARINGLY SOLUBLE IN WATER

Target

TARGET FMS-LIKE TYROSINE KINASE 3 (FLT3)

PDB
6JQR (CRYSTAL STRUCTURE OF FLT3 IN COMPLEX WITH GILTERITINIB)

Ligand code = C6F (link to the list of PDB complexes)

Download experimental 3D coordinates of C6F with added hydrogens

DrugCentral

Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3

Download SDF file

2-Pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-

Formula:
C29H44N8O3

Calculated chemical properties:

MW 552.72
NB_atoms 40
XLogP 2.70
PSA 114.184
NB_HD 4
NB_HA 11
fsp3 0.62
Lipinski(0=no;1=yes) 0

FDA
NDA 211349 (label) INN (GILTERITINIB FUMARATE) XOSPATA (ASTELLAS) APPROVAL= AP YEAR= 2018 NEWMOLECULARENTITY